Serum vascular endothelial growth factor is a candidate biomarker ofmetastatic tumor response to ex vivo gene therapy of renal cell cancer

Angelo A. Baccala; Hua Zhong; Shirley M. Clift; William G. Nelson; Fray F. Marshall; Theodore J. Passe; Neil B. Gambill; Jonathan W. Simons

doi:10.1016/S0090-4295(97)00498-6

Serum vascular endothelial growth factor is a candidate biomarker ofmetastatic tumor response to ex vivo gene therapy of renal cell cancer

Angelo A. Baccala, Hua Zhong, Shirley M. Clift, William G. Nelson, Fray F. Marshall, Theodore J. Passe, Neil B. Gambill, Jonathan W. Simons

School of Medicine

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

We report the close correlation between changes in serum immunoreactive vascular endothelial growth factor 165 (iVEGF₁₆₅) levels and metastatic tumor burden measured by computed tomography scan before treatment, during the antitumor response, and during early progression in a patient treated with ex vivo gene therapy for renal cell carcinoma. With the researcher blinded to outcome, iVEGF levels were measured in archived serum samples from a patient with metastatic renal cell carcinoma who demonstrated a 7-month partial remission to treatment with autologous, irradiated human GM-CSF gene transduced tumor vaccine. Although a spontaneous regression could not be formally excluded in this patient, the appearance of 20 new pulmonary metastases on computed tomography scan after nephrectomy and before vaccination indicates that if spontaneous regression occurred, it took place at the start of vaccine treatment.

Original language	English (US)
Pages (from-to)	327-332
Number of pages	6
Journal	Urology
Volume	51
Issue number	2
DOIs	https://doi.org/10.1016/S0090-4295(97)00498-6
State	Published - Feb 1998

ASJC Scopus subject areas

Urology

Access to Document

10.1016/S0090-4295(97)00498-6

Cite this

@article{64538b06f6f244608be2f24d267320d7,

title = "Serum vascular endothelial growth factor is a candidate biomarker ofmetastatic tumor response to ex vivo gene therapy of renal cell cancer",

abstract = "We report the close correlation between changes in serum immunoreactive vascular endothelial growth factor 165 (iVEGF165) levels and metastatic tumor burden measured by computed tomography scan before treatment, during the antitumor response, and during early progression in a patient treated with ex vivo gene therapy for renal cell carcinoma. With the researcher blinded to outcome, iVEGF levels were measured in archived serum samples from a patient with metastatic renal cell carcinoma who demonstrated a 7-month partial remission to treatment with autologous, irradiated human GM-CSF gene transduced tumor vaccine. Although a spontaneous regression could not be formally excluded in this patient, the appearance of 20 new pulmonary metastases on computed tomography scan after nephrectomy and before vaccination indicates that if spontaneous regression occurred, it took place at the start of vaccine treatment.",

author = "Baccala, {Angelo A.} and Hua Zhong and Clift, {Shirley M.} and Nelson, {William G.} and Marshall, {Fray F.} and Passe, {Theodore J.} and Gambill, {Neil B.} and Simons, {Jonathan W.}",

note = "Funding Information: This work was supported by National Institutes of Health, S.P.O.R.E. in Prostate Cancer CA58230 and CapCURE Foundation (A.B., W.G.N., F.F.M.,J.W.S.) From the Johns Hopkins Oncology Center and Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland; Department of Radiology, Johns Hopkins Hospital, Baltimore, Maryland; and Cell Genesys, Inc., Foster City, California Reprint requests: Angelo A. Baccala, B.S., Johns Hopkins Oncology Center and The Brady Urological Institute, The Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21208 Submitted: June 9, 1997, accepted (with revisions): August 5, 1997",

year = "1998",

month = feb,

doi = "10.1016/S0090-4295(97)00498-6",

language = "English (US)",

volume = "51",

pages = "327--332",

journal = "Urology",

issn = "0090-4295",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Serum vascular endothelial growth factor is a candidate biomarker ofmetastatic tumor response to ex vivo gene therapy of renal cell cancer

AU - Baccala, Angelo A.

AU - Zhong, Hua

AU - Clift, Shirley M.

AU - Nelson, William G.

AU - Marshall, Fray F.

AU - Passe, Theodore J.

AU - Gambill, Neil B.

AU - Simons, Jonathan W.

N1 - Funding Information: This work was supported by National Institutes of Health, S.P.O.R.E. in Prostate Cancer CA58230 and CapCURE Foundation (A.B., W.G.N., F.F.M.,J.W.S.) From the Johns Hopkins Oncology Center and Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland; Department of Radiology, Johns Hopkins Hospital, Baltimore, Maryland; and Cell Genesys, Inc., Foster City, California Reprint requests: Angelo A. Baccala, B.S., Johns Hopkins Oncology Center and The Brady Urological Institute, The Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21208 Submitted: June 9, 1997, accepted (with revisions): August 5, 1997

PY - 1998/2

Y1 - 1998/2

N2 - We report the close correlation between changes in serum immunoreactive vascular endothelial growth factor 165 (iVEGF165) levels and metastatic tumor burden measured by computed tomography scan before treatment, during the antitumor response, and during early progression in a patient treated with ex vivo gene therapy for renal cell carcinoma. With the researcher blinded to outcome, iVEGF levels were measured in archived serum samples from a patient with metastatic renal cell carcinoma who demonstrated a 7-month partial remission to treatment with autologous, irradiated human GM-CSF gene transduced tumor vaccine. Although a spontaneous regression could not be formally excluded in this patient, the appearance of 20 new pulmonary metastases on computed tomography scan after nephrectomy and before vaccination indicates that if spontaneous regression occurred, it took place at the start of vaccine treatment.

AB - We report the close correlation between changes in serum immunoreactive vascular endothelial growth factor 165 (iVEGF165) levels and metastatic tumor burden measured by computed tomography scan before treatment, during the antitumor response, and during early progression in a patient treated with ex vivo gene therapy for renal cell carcinoma. With the researcher blinded to outcome, iVEGF levels were measured in archived serum samples from a patient with metastatic renal cell carcinoma who demonstrated a 7-month partial remission to treatment with autologous, irradiated human GM-CSF gene transduced tumor vaccine. Although a spontaneous regression could not be formally excluded in this patient, the appearance of 20 new pulmonary metastases on computed tomography scan after nephrectomy and before vaccination indicates that if spontaneous regression occurred, it took place at the start of vaccine treatment.

UR - http://www.scopus.com/inward/record.url?scp=0032005485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032005485&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(97)00498-6

DO - 10.1016/S0090-4295(97)00498-6

M3 - Article

C2 - 9495722

AN - SCOPUS:0032005485

SN - 0090-4295

VL - 51

SP - 327

EP - 332

JO - Urology

JF - Urology

IS - 2

ER -

Serum vascular endothelial growth factor is a candidate biomarker ofmetastatic tumor response to ex vivo gene therapy of renal cell cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this